Remco J Molenaar

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 7

Top Topics

Radiation Induced

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Mohammed Khurshed, Èlia Prades-Sagarra, Sarah Saleh, Peter Sminia, Johanna W Wilmink, Remco J Molenaar, Johannes Crezee, Cornelis J F van Noorden
Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1 -Mutated Cancer Cells. Cancers 14 (24) (2022)
Mohammed Khurshed, Èlia Prades-Sagarra, Sarah Saleh, Peter Sminia, Johanna W Wilmink, Remco J Molenaar, Johannes Crezee, Cornelis J F van Noorden
Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1 -Mutated Cancer Cells. Cancers 14 (24) (2022)
Mohammed Khurshed, Èlia Prades-Sagarra, Sarah Saleh, Peter Sminia, Johanna W Wilmink, Remco J Molenaar, Johannes Crezee, Cornelis J F van Noorden
Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1 -Mutated Cancer Cells. Cancers 14 (24) (2022)
Mohammed Khurshed, Remco J Molenaar, Myra E van Linde, Ron A A Mathot, Eduard A Struys, J Tom van Wezel, Cornelis J F van Noorden, Heinz-Josef Klümpen, Judith V M G Bovée, Johanna W Wilmink
A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. Cancers 13 (10) (2021)
Charlotte I Stroes, Sandor Schokker, Remco J Molenaar, Ron A A Mathot, Maarten F Bijlsma, Stephanie O van der Woude, João P Belo Pereira, Gerrit K J Hooijer, Rob H A Verhoeven, Annemieke Cats, Cecile Grootscholten, Johanna W van Sandick, Geert-Jan Creemers, Grard A P Nieuwenhuijzen, Nadia Haj Mohammad, Jelle P Ruurda, Sybren L Meijer, Maarten C C M Hulshof, Mark Ivo van Berge Henegouwen, Hanneke W M van Laarhoven
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers 13 (4) (2021)
Cornelis J F van Noorden, Vashendriya V V Hira, Amber J van Dijck, Metka Novak, Barbara Breznik, Remco J Molenaar
Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy? Cells 10 (3) (2021)
Remco J Molenaar, Jaroslaw P Maciejewski, Johanna W Wilmink, Cornelis J F van Noorden
Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene 37 (15) (2018)